SCHEMBL651355

SCHEMBL651355

O=C1N/C(=N/Cc2cccc(Br)c2)S/C1=C\c1cnc(NC(=O)C2CC2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.46
CDC25B P30305 1/20 0.46
HPGD P15428 4/20 0.42
POLB P06746 2/20 0.42
PKM P14618 1/20 0.42
GSK3B P49841 6/20 0.41
ALOX12 P18054 1/20 0.41
TXK P42681 1/20 0.39
JAK3 P52333 1/20 0.39
BTK Q06187 1/20 0.39
ITK Q08881 1/20 0.39
PIM1 P11309 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
PTPN7 P35236 1/20 0.37
PTPN12 Q05209 1/20 0.37
PTPN22 Q9Y2R2 1/20 0.37
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651064 0.91 PIM1 (0.47) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL10176414 0.90 HPGD (0.53) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL10176413 0.88 PTPN1 (0.44) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL10176412 0.88 GSK3B (0.47) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL651311 0.84 PTPN1 (0.41) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL648559 0.82 SMN1; SMN2 (0.42) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL651957 0.82 LMNA (0.41) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL651249 0.80 LMNA (0.52) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL651248 0.80 LMNA (0.52) PTPN1CDC25BHPGDPOLBPKM
SCHEMBL650973 0.80 LMNA (0.39) PTPN1CDC25BPKMGSK3BJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 PTPN1 1863/4885CDC25B 59/4885HPGD 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.